The Role of Unit-Dose Child-Resistant Packaging in Unintentional Childhood Exposures to Buprenorphine-Naloxone Tablets

Drug Saf. 2020 Feb;43(2):189-191. doi: 10.1007/s40264-019-00883-6.

Authors

Christian Hampp¹, Maribeth C Lovegrove², Daniel S Budnitz², Justin Mathew³, Amy Ho³, Jana McAninch³

Affiliations

¹ Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. Christian.hampp@fda.hhs.gov.
² Medication Safety Program, Division of Healthcare Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
³ Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

No abstract available

Publication types

Letter

MeSH terms

Analgesics, Opioid / administration & dosage
Analgesics, Opioid / poisoning
Buprenorphine, Naloxone Drug Combination / administration & dosage
Buprenorphine, Naloxone Drug Combination / poisoning*
Child, Preschool
Drug Overdose / epidemiology*
Drug Overdose / prevention & control
Drug Overdose / therapy
Drug Packaging / statistics & numerical data*
Emergency Service, Hospital / statistics & numerical data
Humans
Narcotic Antagonists / administration & dosage
Narcotic Antagonists / poisoning
Pediatric Emergency Medicine / statistics & numerical data

Substances

Analgesics, Opioid
Buprenorphine, Naloxone Drug Combination
Narcotic Antagonists

Grants and funding

CC999999/ImCDC/Intramural CDC HHS/United States